Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.6K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.6K
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors01:13

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

1.1K
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
1.1K
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists01:28

Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists

1.1K
Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
1.1K
Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids01:31

Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids

791
In the complex environment of the gastric lumen, excessive acid secretion can lead to the formation or worsening of ulcers within the delicate mucosal layer. Antacids, such as sodium bicarbonate and calcium carbonate, provide relief by neutralizing this acid, transforming it into harmless salt and water. This neutralization process raises the gastric pH from a highly acidic level of 1 to a more basic 3-4, reducing the acidity within the stomach.
However, this neutralization reaction between...
791
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

827
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
827
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

571
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
571

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Discriminating established cardiovascular disease using a novel multiterritory ultrasound plaque burden measure (wTPT): findings from the P-SONAR study.

BMC cardiovascular disorders·2026
Same author

Association between a novel ultrasound-based measure of plaque burden and cardiovascular risk: the P-SONAR study.

Quantitative imaging in medicine and surgery·2026
Same author

Smoking status of patients with acute myocardial infarction in recent randomized clinical trials - actions needed.

Blood pressure·2026
Same author

Effects of lifestyle interventions in pregnancy on gestational diabetes: individual participant data and network meta-analysis.

BMJ (Clinical research ed.)·2026
Same author

Motivational smoking cessation counselling and community-based follow-up after hospitalisation for vascular disease: A randomised controlled trial.

Addiction (Abingdon, England)·2025
Same author

Cue-Restricted Smoking as a behavioral adjunct for smoking cessation: Observational sub-analysis of a randomized trial of deep transcranial magnetic stimulation.

Tobacco prevention & cessation·2025

Related Experiment Video

Updated: Mar 9, 2026

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

14.2K

[Statin intolerance].

Serena Tonstad1

  • 1Seksjon for preventiv kardiologi Avdeling for endokrinologi, sykelig overvekt og forebyggende medisin Oslo universitetssykehus.

Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke
|January 12, 2017
PubMed
Summary
This summary is machine-generated.

Many Norwegians take statins, but reported side effects like muscle pain are common. However, studies show these effects occur similarly to placebo, suggesting management strategies are key.

More Related Videos

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.2K
Estimating the Yield of Compounds on the TLC Plate via the Blue-LED Illumination Technique
06:14

Estimating the Yield of Compounds on the TLC Plate via the Blue-LED Illumination Technique

Published on: October 6, 2022

2.3K

Related Experiment Videos

Last Updated: Mar 9, 2026

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

14.2K
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.2K
Estimating the Yield of Compounds on the TLC Plate via the Blue-LED Illumination Technique
06:14

Estimating the Yield of Compounds on the TLC Plate via the Blue-LED Illumination Technique

Published on: October 6, 2022

2.3K

Area of Science:

  • Pharmacology
  • Clinical Medicine
  • Public Health

Background:

  • In 2015, over 530,000 individuals in Norway were prescribed statins.
  • Musculoskeletal and non-specific adverse effects are frequently reported with statin use.
  • Reported adverse effect prevalence contrasts with findings from randomized controlled trials (RCTs) where rates align with placebo.

Purpose of the Study:

  • To address the discrepancy between reported statin adverse effects and RCT findings.
  • To outline management strategies for patients experiencing statin-related adverse effects.

Main Methods:

  • Review of prescription data and adverse effect reporting in Norway.
  • Comparison with existing literature, particularly randomized controlled trials.
  • Identification of common management approaches for statin intolerance.

Main Results:

  • A significant number of individuals in Norway use statins.
  • A notable incidence of reported adverse effects, especially musculoskeletal.
  • RCTs indicate statin adverse effect rates are comparable to placebo.

Conclusions:

  • Despite frequent reports, statin-induced adverse effects may be overemphasized in clinical practice compared to placebo rates.
  • Effective management strategies for statin-associated adverse effects include treatment breaks, dose adjustments, medication switching, and co-prescription of other lipid-lowering drugs.